The assay uses nasal swab samples to detect Covid-19. Credit: Prasesh Shiwakoti (Lomash) / Unsplash.

Nanomix has resubmitted an application to the US Food and Drug Administration (FDA) seeking emergency use authorization (EUA) for its eLab COVID-19 rapid antigen test.

The latest move follows the submission of an application for EUA to the FDA for the same product in February.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The new application from Nanomix includes clinical development documentation as well as additional analytical data in response to review comments from the FDA.

The portable, handheld eLab COVID-19 rapid antigen test, which runs on the portable Nanomix eLab analyser, delivers results within 15 minutes.

It delivers laboratory-quality results in any setting to help expand the access and availability of testing for Covid-19.

The assay uses nasal swab samples and detects nucleocapsid antigens from SARS-CoV-2.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A swab and nasal sample collection tube are used to collect samples from the user and transferred to the single-use, microfluidic cartridge.

The cartridge can print or deliver results electronically through Bluetooth.

The point-of-care antigen system can also publish the test results as a QR code for privacy.

Nanomix president and CEO David Ludvigson said: “We look forward to the FDA’s review of our application and are proud of the work our team has done to develop a rapid, portable Covid-19 antigen test during this critical time.

“If authorised by the FDA, we believe our mobile point-of-care system will greatly increase accessibility to Covid-19 testing.”

The company stated that the development project secured federal funds, either in whole or in part, from the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, and Biomedical Advanced Research and Development Authority (BARDA) Division of Research Innovation and Ventures.